SCOPE: Epidemiologic evidence suggests diets rich in cruciferous vegetables, particularly broccoli, are associated with lower bladder cancer risk. Our objectives are to investigate these observations and determine the role of isothiocyanates in primary or secondary bladder cancer prevention. METHODS AND RESULTS: We initially investigate the mechanisms whereby broccoli and broccoli sprout extracts and pure isothiocyanates inhibit normal, noninvasive (RT4), and invasive (J82, UMUC3) human urothelial cell viability. Sulforaphane (IC(50) = 5.66 ± 1.2 μM) and erucin (IC(50) = 8.79 ± 1.3 μM) are found to be the most potent inhibitors and normal cells are least sensitive. This observation is associated with downregulation of survivin, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/neu), G(2) /M cell cycle accumulation, and apoptosis. In a murine UMUC3 xenograft model, we fed semipurified diets containing 4% broccoli sprouts, or 2% broccoli sprout isothiocyanate extract; or gavaged pure sulforaphane or erucin (each at 295 μmol/kg, similar to dietary exposure); and report tumor weight reduction of 42% (p = 0.02), 42% (p = 0.04), 33% (p = 0.04), and 58% (p < 0.0001), respectively. Sulforaphane and erucin metabolites are present in mouse plasma (micromolar range) and tumor tissue, with N-acetylcysteine conjugates as the most abundant. Interconversion of sulforaphane and erucin metabolites was observed. CONCLUSION: This work supports development of fully characterized, novel food products containing broccoli components for phase I/II human studies targeting bladder cancer prevention.
SCOPE: Epidemiologic evidence suggests diets rich in cruciferous vegetables, particularly broccoli, are associated with lower bladder cancer risk. Our objectives are to investigate these observations and determine the role of isothiocyanates in primary or secondary bladder cancer prevention. METHODS AND RESULTS: We initially investigate the mechanisms whereby broccoli and broccoli sprout extracts and pure isothiocyanates inhibit normal, noninvasive (RT4), and invasive (J82, UMUC3) human urothelial cell viability. Sulforaphane (IC(50) = 5.66 ± 1.2 μM) and erucin (IC(50) = 8.79 ± 1.3 μM) are found to be the most potent inhibitors and normal cells are least sensitive. This observation is associated with downregulation of survivin, epidermal growth factor receptor (EGFR) and humanepidermal growth factor receptor 2 (HER2/neu), G(2) /M cell cycle accumulation, and apoptosis. In a murine UMUC3 xenograft model, we fed semipurified diets containing 4% broccoli sprouts, or 2% broccoli sprout isothiocyanate extract; or gavaged pure sulforaphane or erucin (each at 295 μmol/kg, similar to dietary exposure); and report tumor weight reduction of 42% (p = 0.02), 42% (p = 0.04), 33% (p = 0.04), and 58% (p < 0.0001), respectively. Sulforaphane and erucin metabolites are present in mouse plasma (micromolar range) and tumor tissue, with N-acetylcysteine conjugates as the most abundant. Interconversion of sulforaphane and erucin metabolites was observed. CONCLUSION: This work supports development of fully characterized, novel food products containing broccoli components for phase I/II human studies targeting bladder cancer prevention.
Authors: D S Michaud; D Spiegelman; S K Clinton; E B Rimm; G C Curhan; W C Willett; E L Giovannucci Journal: N Engl J Med Date: 1999-05-06 Impact factor: 91.245
Authors: Ahmed A Al Janobi; Richard F Mithen; Amy V Gasper; P Nicholas Shaw; Richard J Middleton; Catharine A Ortori; David A Barrett Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2006-08-23 Impact factor: 3.205
Authors: Martijn Vermeulen; Robin van den Berg; Andreas P Freidig; Peter J van Bladeren; Wouter H J Vaes Journal: J Agric Food Chem Date: 2006-07-26 Impact factor: 5.279
Authors: Rex Munday; Paulette Mhawech-Fauceglia; Christine M Munday; Joseph D Paonessa; Li Tang; John S Munday; Carolyn Lister; Paula Wilson; Jed W Fahey; Warren Davis; Yuesheng Zhang Journal: Cancer Res Date: 2008-02-29 Impact factor: 12.701
Authors: Michael T Buckley; Joanne Yoon; Herman Yee; Luis Chiriboga; Leonard Liebes; Gulshan Ara; Xiaozhong Qian; Dean F Bajorin; Tung-Tien Sun; Xue-Ru Wu; Iman Osman Journal: J Transl Med Date: 2007-10-12 Impact factor: 5.531
Authors: Besma Abbaoui; Kelly H Telu; Christopher R Lucas; Jennifer M Thomas-Ahner; Steven J Schwartz; Steven K Clinton; Michael A Freitas; Amir Mortazavi Journal: J Proteomics Date: 2017-01-27 Impact factor: 4.044
Authors: Mohammad Aghajanpour; Mohamad Reza Nazer; Zia Obeidavi; Mohsen Akbari; Parya Ezati; Nasroallah Moradi Kor Journal: Am J Cancer Res Date: 2017-04-01 Impact factor: 6.166
Authors: Besma Abbaoui; Christopher R Lucas; Ken M Riedl; Steven K Clinton; Amir Mortazavi Journal: Mol Nutr Food Res Date: 2018-08-29 Impact factor: 5.914
Authors: Gregory V Bricker; Kenneth M Riedl; Robin A Ralston; Kathleen L Tober; Tatiana M Oberyszyn; Steven J Schwartz Journal: Mol Nutr Food Res Date: 2014-07-28 Impact factor: 5.914
Authors: Dushani L Palliyaguru; Dionysios V Chartoumpekis; Nobunao Wakabayashi; John J Skoko; Yoko Yagishita; Shivendra V Singh; Thomas W Kensler Journal: Free Radic Biol Med Date: 2016-10-04 Impact factor: 7.376